Cellectis
Yahoo Finance • last month
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Ha... Full story
Yahoo Finance • 2 years ago
Monthly information on share capital and company voting rights
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights05/31/202355,583,76861,505,063 About Cellectis Cellectis i... Full story
Yahoo Finance • 2 years ago
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
NEW YORK, 13 juin 2023 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/05/202355 583 76861 505 063 À propos de Ce... Full story
Yahoo Finance • 2 years ago
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c... Full story
Yahoo Finance • 3 years ago
Cellectis to Report Second Quarter 2022 Financial Results
Cellectis Inc. NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies... Full story
Yahoo Finance • 3 years ago
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
Cellectis Inc. NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France. At the meeting, during... Full story
Yahoo Finance • 3 years ago
Why Cellectis' Shares Rose 22.7% This Week
Shares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence. The company released research data on its new univer... Full story
Yahoo Finance • 3 years ago
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cellsPreclinical data shows proof-of-principle that UCART123 cells have potent anti-BPDCN activityHuman evaluati... Full story
Yahoo Finance • 3 years ago
Cellectis publie deux articles dans Nature Communications démontrant une validation préclinique solide du produit candidat UCART123 pour traiter la LAM et le TCPDB
Les données précliniques démontrent que le produit candidat UCART123 élimine efficacement la leucémie myéloblastique aigüe (LAM) sans impact majeur sur les cellules progénitrices hématopoïétiques Les données précliniques démontrent que les... Full story
